API | talotrexin

talotrexin Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Chemistry

SMILES: Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1
InChIKey: NYQPLPNEESYGNO-IBGZPJMESA-N
Mol. Mass: 573.57
ALogP: 1.29 Partition coefficient
ChEMBL Molecules:

talotrexin

talotrexin ammonium

More Chemistry

Pharmacology

Mechanism of Action:
- Folate receptor alpha (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

n(alpha)-(4-amino-4-deoxypteroyl)-n(delta)-hemiphthaloyl-l-ornithine | pt523 | pt 523 | pt-523 | talotrexin | talotrexin ammonium

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (1)

Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (5)

Brain Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Leukemia (Phase 1/Phase 2)

Lymphoma (Phase 1)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue